Today The Allergan PLC. (AGN) Stake Decreased by Whitebox Advisors LLC

Today The Allergan PLC. (AGN) Stake Decreased by Whitebox Advisors LLC

Whitebox Advisors LLC decreased its stake in Allergan PLC. (NYSE:AGN) by 4.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 48,699 shares of the company’s stock after selling 2,150 shares during the period. Allergan PLC. makes up approximately 0.5% of Whitebox Advisors LLC’s investment portfolio, making the stock its 27th largest position. Whitebox Advisors LLC’s holdings in Allergan PLC. were worth $11,216,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of AGN. Jackson Square Partners LLC boosted its stake in Allergan PLC. by 5.7% in the second quarter. Jackson Square Partners LLC now owns 3,840,160 shares of the company’s stock valued at $1,004,656,000 after buying an additional 205,701 shares in the last quarter. General Electric Co. boosted its stake in Allergan PLC. by 13.7% in the second quarter. General Electric Co. now owns 2,676,658 shares of the company’s stock valued at $618,549,000 after buying an additional 322,108 shares in the last quarter. Veritas Asset Management LLP acquired a new position in shares of Allergan PLC. during the second quarter valued at approximately $492,177,000. Thornburg Investment Management Inc. increased its position in shares of Allergan PLC. by 133.2% in the second quarter. Thornburg Investment Management Inc. now owns 1,717,844 shares of the company’s stock valued at $396,977,000 after buying an additional 981,355 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. increased its position in shares of Allergan PLC. by 12.6% in the second quarter. Adage Capital Partners GP L.L.C. now owns 1,402,893 shares of the company’s stock valued at $324,195,000 after buying an additional 156,959 shares during the last quarter. 87.74% of the stock is owned by institutional investors and hedge funds.

Shares of Allergan PLC. (NYSE:AGN) traded down 0.411% during trading on Wednesday, hitting $212.235. The company had a trading volume of 300,290 shares. The company’s 50 day moving average is $205.03 and its 200 day moving average is $224.49. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $301.32. The firm has a market capitalization of $79.61 billion, a P/E ratio of 5.952 and a beta of 1.02.

Allergan PLC. (NYSE:AGN) last announced its quarterly earnings data on Wednesday, November 2nd. The company reported $3.32 earnings per share for the quarter, missing the Zacks’ consensus estimate of $3.65 by $0.33. The firm had revenue of $3.62 billion for the quarter, compared to analysts’ expectations of $3.73 billion. Allergan PLC. had a net margin of 93.74% and a return on equity of 7.26%. The business’s quarterly revenue was up 4.4% on a year-over-year basis. During the same period in the prior year, the business posted $3.48 earnings per share. Analysts anticipate that Allergan PLC. will post $13.39 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 28th. Investors of record on Tuesday, February 28th will be issued a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.31%. This is a boost from Allergan PLC.’s previous quarterly dividend of $0.05. The ex-dividend date is Friday, February 24th.

Several research analysts have commented on AGN shares. Goldman Sachs Group, Inc. (The) downgraded Allergan PLC. from a “conviction-buy” rating to a “buy” rating in a research note on Wednesday, December 21st. Deutsche Bank AG reissued a “buy” rating and set a $247.00 target price (up previously from $245.00) on shares of Allergan PLC. in a research note on Friday, December 23rd. J P Morgan Chase & Co set a $300.00 target price on Allergan PLC. and gave the stock a “buy” rating in a research note on Monday, December 5th. RBC Capital Markets reissued an “outperform” rating and set a $279.00 target price (down previously from $300.00) on shares of Allergan PLC. in a research note on Thursday, November 3rd. Finally, William Blair reissued a “market perform” rating on shares of Allergan PLC. in a research note on Monday, November 21st. Seven research analysts have rated the stock with a hold rating and twenty have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $270.72.

In related news, CEO Brent L. Saunders purchased 5,250 shares of the firm’s stock in a transaction on Monday, November 21st. The shares were acquired at an average cost of $189.13 per share, with a total value of $992,932.50. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Maria Teresa Hilado purchased 1,422 shares of the firm’s stock in a transaction on Friday, November 11th. The stock was bought at an average cost of $210.64 per share, for a total transaction of $299,530.08. Following the completion of the purchase, the chief financial officer now directly owns 12,659 shares in the company, valued at $2,666,491.76. The disclosure for this purchase can be found here. 0.27% of the stock is owned by insiders.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Related posts

Leave a Comment